Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.48 is 85% above its 5-year average of -3.18, near the high end of its 5-year range (-6.10–-0.48).
51.52% above its 12-month average of -0.99.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.10.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.48
EARNINGS PER SHARE (EPS) AVG TTM
-0.99
EARNINGS PER SHARE (EPS) AVG 3Y
-1.87
EARNINGS PER SHARE (EPS) AVG 5Y
-3.18
EARNINGS PER SHARE (EPS) AVG 10Y
-19.04
EARNINGS PER SHARE (EPS) AVG 15Y
-111.64
EARNINGS PER SHARE (EPS) AVG 20Y
-470.30
CURRENT VS TTM AVG
+51.52%
CURRENT VS 3Y AVG
+74.37%
CURRENT VS 5Y AVG
+84.89%
CURRENT VS 10Y AVG
+97.48%
CURRENT VS 15Y AVG
+99.57%
CURRENT VS 20Y AVG
+99.90%
Marker Therapeutics, Inc.
Market Cap
$17.01M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.99
3Y Avg
-1.87
5Y Avg
-3.18
Market Cap
$17.23M
Earnings Per Share (EPS)
-1.87
TTM Avg
-0.88
3Y Avg
-1.76
5Y Avg
-2.28
Market Cap
$16.70M
Earnings Per Share (EPS)
-3.73
TTM Avg
-46.49
3Y Avg
-194.14
5Y Avg
-195.03
Market Cap
$16.73M
Earnings Per Share (EPS)
-4.76
TTM Avg
-17.55
3Y Avg
-9.83
5Y Avg
-7.78
Market Cap
$16.40M
Earnings Per Share (EPS)
-0.21
TTM Avg
-0.22
3Y Avg
-0.25
5Y Avg
-0.30
Market Cap
$16.98M
Earnings Per Share (EPS)
-16.36
TTM Avg
46.76
3Y Avg
-158.09
5Y Avg
-209.03
Market Cap
$17.73M
Earnings Per Share (EPS)
-0.66
TTM Avg
-0.90
3Y Avg
-9.28
5Y Avg
-9.88
Market Cap
$16.00M
Earnings Per Share (EPS)
-0.76
TTM Avg
-2.06
3Y Avg
-5.59
5Y Avg
-9.29
Market Cap
$15.78M
Earnings Per Share (EPS)
-13.07
TTM Avg
-13.67
3Y Avg
-19.10
5Y Avg
-23.67
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | $17.01M | -0.48 | -0.99 | -1.87 | -3.18 |
| Lipocine Inc. (LPCN)vs › | $17.23M | -1.87 | -0.88 | -1.76 | -2.28 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.70M | -3.73 | -46.49 | -194.14 | -195.03 |
| Palatin Technologies, Inc. (PTN)vs › | $16.73M | -4.76 | -17.55 | -9.83 | -7.78 |
| Dyadic International, Inc. (DYAI)vs › | $16.40M | -0.21 | -0.22 | -0.25 | -0.30 |
| PAVmed Inc. (PAVM)vs › | $16.98M | -16.36 | 46.76 | -158.09 | -209.03 |
| Cosmos Health Inc. (COSM)vs › | $17.73M | -0.66 | -0.90 | -9.28 | -9.88 |
| BioCardia, Inc. (BCDA)vs › | $16.00M | -0.76 | -2.06 | -5.59 | -9.29 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.78M | -13.07 | -13.67 | -19.10 | -23.67 |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.65M | -0.78 | -8.29 | -9461.74 | -302593.36 |
Trailing EPS (TTM)
$-0.48
Forward EPS (Est.)
$-0.59
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.79 |
| 2024-12-31 | -1.19 |
| 2023-12-31 | -1.93 |
| 2022-12-31 | -3.58 |
| 2021-12-31 | -5.47 |
| 2020-12-31 | -6.10 |
| 2019-12-31 | -4.70 |
| 2018-12-31 | -77.50 |
| 2017-12-31 | -11.62 |
| 2016-12-31 | -3.56 |
| 2015-12-31 | -93.02 |
| 2014-12-31 | -239.63 |
| 2013-12-31 | -584.40 |
| 2012-12-31 | -1072.88 |
| 2011-12-31 | -529.47 |
| 2010-12-31 | -1535.18 |
| 2009-12-31 | -1396.11 |
| 2008-12-31 | -1124.39 |
| 2007-12-31 | -2244.18 |
| 2006-12-31 | -1304387.00 |
| 2005-12-31 | -989558.00 |
| 2004-12-31 | -2683105.00 |
| 2003-12-31 | -5778905.00 |
| 2002-12-31 | -2284709.00 |
| 2001-12-31 | -384540.00 |
| 2000-12-31 | -1291831.00 |
| 1999-12-31 | -1127327.00 |
